Volume 10 | June 7, 2023
With 15 days to FACTOR, our annual osteosarcoma conference, we are giddy with excitement and anticipation of seeing our community together in one place. Intellectual sparks fly, energy ignites, connections are created, and trails are blazed. So much good happens when the community comes together like these recent collaborations.
MIB Agents looks forward to continuing the funding momentum when we announce our OutSmarting Osteosarcoma 2023 grant recipients next week and present the awards live at FACTOR. We can't wait to see you there!
With hope,
Ann
And 15 reasons to attend FACTOR!
.png)
Join us for our 3rd annual OutBidding Osteosarcoma auction, featuring exclusive items and experiences! Our incredible donors who Make It Better for kids with osteosarcoma have contributed generously with wonderful and one of a kind items in Luxury Hotels & Travel Adventures, Original Art, Home Goods & Beauty, and Unique items & Experiences. Bid now! We encourage you to share the OutBidding Osteosarcoma auction link and details with your family, friends, and community. Together, we can Make It Better!
Auction ends June 11th, 5 PM EST.
OutSmarting Osteosarcoma recipients Matteo Trucco, MD from Cleveland Clinic and Kurt Weiss, MD from University of Pittsburgh were featured on CBS News Talk Pittsburgh talking about their collaboration and the resulting Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas trial funded in part by MIB Agents.
.jpg)
Every month, OsteoWarriors receive Warrior Mail - monthly letters of hope and cheer from MIB Agent Writers around the world. OsteoWarrior Aiden and his family who are active Agent Writers share Aiden’s osteosarcoma story, their advice for other families managing an osteosarcoma diagnosis, why they write for Warrior Mail, and what motivated them to start a MIB Agents Family Fund.
Read More About the Beutlich Family
If you have a job posting and you would like it included here, please email christina@mibagents.org.
Watch Past Episodes and See the Upcoming Schedule
.png)
A virtual tumor review board for osteosarcoma, TURBO is open to global clinicians or researchers with an interest in osteosarcoma. Patients and families are welcome to ask their oncologists to present a case on their behalf. Join TURBO to request an invite or submit a case.
Next meeting: June 14th at 5pm ET
In partnership with the National Cancer Institute (NCI), the Society for Immunotherapy of Cancer (SITC) is launching their third "SITC-NCI Computational Immuno-Oncology Webinar Series" throughout 2023. These free-to-attend digital events will help individual research labs to embrace the computational challenges of analyzing and integrating diverse assay data across the spectrum of immuno-oncology. Organized by the SITC Big Data and Data Sharing Committee, these one-hour webinars will help participants foster better communication concerning data science technologies and analyses between cancer immunotherapy researchers and clinicians in order to fuel translational immunotherapy research.
The MIB Agents Ambassador Agents program connects osteosarcoma patients and families to the osteosarcoma survivors and their families. Ambassador Agents have walked the osteosarcoma path and are dedicated to providing support and hope to individuals who are in treatment now.
Our next Ambassador Agent training will be held in-person on June 23rd in Atlanta prior to the FACTOR conference. Email isabel@mibagents.org to learn more.
To make a significant impact for kids fighting osteosarcoma, five funding partners have banded together with St. Baldrick’s to support a new Fighting Osteosarcoma Together Super Grant. The recipient of this three-year, $1.5 million grant is Dr. Patrick Grohar, at the Children’s Hospital of Philadelphia. Dr. Grohar and colleagues will investigate the role of the MYC gene in osteosarcoma with plans to find compounds that are not only tailored to MYC-amplified osteosarcoma but are also effective treatment options. The team will explore various approaches, such as utilizing these compounds alone, in combination with chemotherapy, or specifically targeting metastasis prevention.
The Liddy Shriver Early Career Research Award is intended to recognize, with an elite international award and lecture, an outstanding early-career researcher working in the sarcoma field. It is not primarily an award for future research, but an award based on track record of early achievement, and is intended to be international in scope. An important aspect of this award is the lecture at CTOS and subsequent publishing of the lecture. Nomination packets are to be submitted by the deadline of August 15th, 2023.
If you have a trial that is currently enrolling osteosarcoma patients, please email christina@mibagents.org.
.jpg)
